

Jamie E Chaft

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5190623/publications.pdf>

Version: 2024-02-01

97
papers

17,060
citations

41323

49
h-index

37183

96
g-index

100
all docs

100
docs citations

100
times ranked

19435
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab. <i>Radiotherapy and Oncology</i> , 2022, 167, 158-164.	0.3	10
2	Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 546-555.	0.8	84
3	Impact of Tumor Mutational Burden and Gene Alterations Associated with Radiation-Response on Outcomes of Post-Operative Radiation Therapy in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	8
4	Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	8
5	Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. , 2022, 10, e004688.		34
6	Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100615.	0.6	6
7	Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation Therapy. <i>Practical Radiation Oncology</i> , 2021, 11, e52-e62.	1.1	18
8	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. <i>JAMA Surgery</i> , 2021, 156, e205601.	2.2	52
9	Evolution of systemic therapy for stages III non-metastatic non-small-cell lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 547-557.	12.5	152
10	Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. <i>Future Oncology</i> , 2021, 17, 4045-4055.	1.1	76
11	Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100197.	0.6	3
12	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100187.	0.6	11
13	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , 2021, 596, 126-132.	13.7	234
14	Increasing Heart Dose Reduces Overall Survival in Patients Undergoing Postoperative Radiation Therapy for NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100209.	0.6	7
15	The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1392-1402.	0.5	12
16	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021, 159, 66-73.	0.9	17
17	Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 144, 101-104.	0.3	21
18	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2020, 10, 1842-1853.	7.7	179

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282.		108
20	Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab. Cancer Medicine, 2020, 9, 4622-4631.	1.3	37
21	Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers. JAMA Oncology, 2020, 6, 1048.	3.4	96
22	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	0.5	205
23	Clinical outcomes, local regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. Radiotherapy and Oncology, 2020, 149, 205-211.	0.3	39
24	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1327-1337.	3.2	90
25	Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e159-e170.	1.8	7
26	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical Cancer Research, 2020, 26, 2849-2858.	3.2	74
27	Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. British Journal of Anaesthesia, 2020, 124, 251-260.	1.5	35
28	Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. Journal of Clinical Oncology, 2019, 37, 3546-3555.	0.8	78
29	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2019, 37, 97-104.	0.8	159
30	Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 269-276.	0.4	218
31	Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2019, 14, 482-493.	0.5	81
32	Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 743-753.e3.	0.4	30
33	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	9.4	2,702
34	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Research, 2019, 79, 1214-1225.	0.4	226
35	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute, 2019, 111, 575-583.	3.0	96
36	Adrenal Metastasectomy in the Presence and Absence of Extraadrenal Metastatic Disease. Annals of Surgery, 2019, 270, 373-377.	2.1	22

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.	13.9	1,495
38	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	7.7	827
39	KEYNOTE-024: Unlocking a pathway to lung cancer cure?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1777-1780.	0.4	10
40	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	5.1	486
41	Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, e131-e140.	1.1	10
42	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2872-2878.	0.8	747
43	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	0.8	1,109
44	Immunotherapy in surgically resectable non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S404-S411.	0.6	53
45	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	0.5	133
46	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10119-E10126.	3.3	180
47	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1733-1742.	0.5	120
48	Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. <i>Advances in Radiation Oncology</i> , 2018, 3, 391-398.	0.6	33
49	Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. <i>Cancer Immunology Research</i> , 2018, 6, 1093-1099.	1.6	258
50	Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 106, 848-855.	0.7	17
51	Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. <i>Lung Cancer</i> , 2018, 122, 67-71.	0.9	35
52	<i>YES1</i> amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6030-E6038.	3.3	44
53	The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis. <i>Clinical Lung Cancer</i> , 2017, 18, 255-258.	1.1	2
54	Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery. <i>Clinical Lung Cancer</i> , 2017, 18, e161-e168.	1.1	17

#	ARTICLE	IF	CITATIONS
55	OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1 ⁺ Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, S251-S252.	0.5	13
56	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	7.7	490
57	Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. <i>Lung Cancer</i> , 2017, 108, 205-211.	0.9	42
58	Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors. <i>Annals of Thoracic Surgery</i> , 2017, 104, e217-e218.	0.7	69
59	Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stages I to IIIA Resectable Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 449-451.	2.5	7
60	Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2960-2974.	0.8	258
61	Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. <i>Annals of Translational Medicine</i> , 2017, 5, 479-479.	0.7	11
62	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1 ⁺ Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	24
63	ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1 ⁺ Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results. <i>Journal of Thoracic Oncology</i> , 2016, 11, S251-S252.	0.5	14
64	Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2016, 101, 1052-1059.	0.7	28
65	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016, 4, 383-389.	1.6	247
66	Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers. <i>Lung Cancer</i> , 2016, 99, 53-56.	0.9	45
67	Adaptive Neoadjuvant Chemotherapy Guided by 18 F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. <i>Journal of Thoracic Oncology</i> , 2016, 11, 537-544.	0.5	42
68	Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. <i>Lancet Oncology</i> , The, 2016, 17, 299-308.	5.1	556
69	HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2016, 11, 414-419.	0.5	205
70	Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 35241-35256.	0.8	17
71	Have adjuvant tyrosine kinase inhibitors lost their shine?. <i>Annals of Translational Medicine</i> , 2016, 4, 285-285.	0.7	1
72	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5439-5444.	3.2	104

#	ARTICLE	IF	CITATIONS
73	Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1713-1719.	0.5	84
74	Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival. <i>Journal of Clinical Oncology</i> , 2015, 33, 2877-2884.	0.8	181
75	HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. <i>Lung Cancer</i> , 2015, 90, 617-619.	0.9	34
76	Chemotherapy for Lung Cancers: Here to Stay. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e375-e380.	1.8	4
77	Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. <i>Lancet Oncology</i> , The, 2014, 15, e42-e50.	5.1	427
78	Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis. <i>Cell</i> , 2014, 156, 1002-1016.	13.5	672
79	Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation. <i>Clinical Lung Cancer</i> , 2014, 15, 405-410.	1.1	63
80	Association of <i>KRAS</i> and <i>EGFR</i> mutations with survival in patients with advanced lung adenocarcinomas. <i>Cancer</i> , 2013, 119, 356-362.	2.0	143
81	Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 453-461.	1.1	12
82	Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. <i>Science Translational Medicine</i> , 2013, 5, 216ra177.	5.8	438
83	<i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 220-229.	1.9	367
84	Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 931-934.	1.1	1
85	Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. <i>Modern Pathology</i> , 2013, 26, 511-522.	2.9	95
86	Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non-Small-Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1084-1090.	0.5	111
87	Lungs Don't Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2013, 8, 123-125.	0.5	33
88	The Management of Patients With Stage IIIA Non-Small Cell Lung Cancer With N2 Mediastinal Node Involvement. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 599-613.	2.3	65
89	Clinical Outcomes with Perioperative Chemotherapy in Sarcomatoid Carcinomas of the Lung. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1400-1405.	0.5	42
90	Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1815-1822.	0.5	160

#	ARTICLE	IF	CITATIONS
91	ALK-Rearranged Lung Cancer: Adenosquamous Lung Cancer Masquerading as Pure Squamous Carcinoma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 768-769.	0.5	47
92	Prevalence, Clinicopathologic Associations, and Molecular Spectrum of <i>ERBB2</i> (<i>HER2</i>) Tyrosine Kinase Mutations in Lung Adenocarcinomas. <i>Clinical Cancer Research</i> , 2012, 18, 4910-4918.	3.2	407
93	Coexistence of <i>PIK3CA</i> and Other Oncogene Mutations in Lung Adenocarcinoma—Rationale for Comprehensive Mutation Profiling. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 485-491.	1.9	191
94	Incorporation of Crizotinib into the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1328-1330.	2.3	18
95	Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i> -Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design. <i>Clinical Cancer Research</i> , 2011, 17, 6298-6303.	3.2	383
96	Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the <i>EGFR</i> Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the <i>EGFR</i> Gene. <i>Clinical Cancer Research</i> , 2011, 17, 3500-3506.	3.2	66
97	Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 178-185.	1.3	21